State Rep. Jacob Rosecrants, D-Norman, will lead an interim study in October examining Oklahoma’s medical marijuana testing standards, transparency requirements andpublichealth outcomes. The study will review the state’s current regulatory framework for medical marijuana testing and product safety, with a focus on whether patients and consumers have adequate information about the products they purchase and use.
Amongtheissuesexpected to be examined are testing standards, laboratory requirements, compliance procedures, product recall processes and state oversight mechanisms. The study will seek to identify areas where the current system is working effectively, as well as potential gaps that could be addressed through policy changes.
“Medical marijuana patients inOklahomadeserveto know that the products they rely on are safe, accurately tested, and held to consistent standards,” Rosecrants said.
Rosecrants noted that the interim study will provide an opportunity for regulators, medical marijuana patients, laboratories and industry representatives to discuss the state’s existing system and possible improvements.
“This interim study is an opportunity to bring regulators, patients, laboratories, and industry stakeholders to the same table, examine what’s working and what isn’t, and identify ways to strengthen safety, transparency, accountability, and public confidence in Oklahoma’s medical marijuana program,” he said.
The study is intended to develop practical policy recommendations aimed at increasing transparency and strengthening consumer protections within Oklahoma’s medical marijuana marketplace. The discussion comes as Oklahoma continues to regulate one of the nation’s largest medical marijuana markets, making testing and product safety important issues for patients, businesses and state regulators.
Theinterimstudyisscheduled for Oct. 13, 2026, from 9:30 a.m. to 12:30 p.m. The meeting will be livestreamed throughtheOklahomaHouse of Representatives website.
The study will give lawmakers and stakeholders an opportunity to examine whether Oklahoma’s existing testing and oversight requirements provide sufficient safeguards while also identifying potential changes to improve consistency and public confidence in the medical marijuana program.